Arsenic trioxide for the treatment of acute promyelocytic leukemia

Cancer Practice

Volumn 9, Issue 3, 2001, Pages 155-157

  Lam, M S H ^a   Ignoffo, R J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER RECURRENCE; CARDIOTOXICITY; COUGHING; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTOSIS; LIVER DYSFUNCTION; NEUROTOXICITY; RETINOIC ACID SYNDROME; SHORT SURVEY; SKIN MANIFESTATION;

ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES;

EID: 0035041051     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.2001.009003155.x     Document Type: Article

References (29)

1. Acute promyelocytic leukemia
2. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: A GIMEMA retrospective study in 268 consecutive patients
3. Acute promyelocytic leukemia: A curable disease
4. Current issues in the management of acute promyelocytic leukemia
5. The acute promyelocytic leukemia-specific PML-RAR fusion protein inhibits differentiation and promotes survival of myeloid precursor cells
6. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
7. All-trans retinoic acid given concurrently with induction chemotherapy improves the outcome of APL: Results of the UK MRC ATRA trial
8. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia: European APL group
9. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
10. Multiple mechanisms are involved in differentiation induced by arsenic trioxide in acute promyelocytic leukemia
11. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
12. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collpase and retinoic acid signaling pathways in acute promyelocytic leukemia
13. 3) ± all-trans retinoic acid (ATRA): The French As98 Study
14. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
15. 3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells
16. Arsenic trioxide treated 72 cases of acute promyelocytic leukaemia
17. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
18. U.S. Multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
19. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
20. 3 and ATRA in the treatment of acute premyelocytic leukemia (APL)
21. Leukocytosis and the retinoic acid syndrome in patients with acute promyelovytic leukemia treated with arsenic trioxide
22. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia
23. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide
24. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukemia
25. Treatment of relapsed acute promyelocytic leukemia patients with low dose As2O3
26. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro
27. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro